Efficacy and Safety of HCP1102 Capsule
Phase 3
Completed
- Conditions
- Asthma With Allergic Rhinitis
- Interventions
- Drug: HCP1102+HGP0711PlaceboDrug: HCP1102Placebo+HGP0711
- Registration Number
- NCT02552667
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Brief Summary
Efficacy and safety of HCP1102 capsule : A randomized, double-blind, active-controlled, multicenter phase 3 clinical trial.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 228
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description HCP1102+HGP0711Placebo HCP1102+HGP0711Placebo HCP1102Placebo+HGP0711Placebo(1week) -\> HCP1102+HGP0711Placebo(4weeks) Each 1 capsule, once daily HCP1102Placebo+HGP0711 HCP1102Placebo+HGP0711 HCP1102Placebo+HGP0711Placebo(1week) -\> HCP1102Placebo+HGP0711(4weeks) Each 1 capsule, once daily
- Primary Outcome Measures
Name Time Method Change of Mean Daytime Nasal Symptom Score base line, 3-4week(2weeks)
- Secondary Outcome Measures
Name Time Method Change of Runny nose (Mean Daytime Nasal Symptom Score) base line, 1-2week(2weeks), 3-4week(2weeks) Change of pruritus (Mean Daytime Nasal Symptom Score) base line, 1-2week(2weeks), 3-4week(2weeks) Change of Mean Nighttime Nasal Symptom Score base line, 1-2week(2weeks), 3-4week(2weeks) Change of Mean Daytime Nasal Symptom Score base line, 1-2week(2weeks), 3-4week(2weeks) Change of Mean Composite Symptom Score base line, 1-2week(2weeks), 3-4week(2weeks) Change of sneezing (Mean Daytime Nasal Symptom Score) base line, 1-2week(2weeks), 3-4week(2weeks)
Trial Locations
- Locations (1)
Soon Chun Hyang University Hospital Bucheon
🇰🇷Bucheon, Gyunggi -do, Korea, Republic of